ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications

Cancers (Basel). 2023 Dec 18;15(24):5886. doi: 10.3390/cancers15245886.

Abstract

Receptor tyrosine kinases, or RTKs, are one large family of cell surface receptors involved in signal transduction, which represent an integral part of the signaling pathways. They play a crucial role in most important cellular processes, starting with the cell cycle, proliferation and differentiation, as well as cell migration, metabolism and survival. The introduction of ImmunoPET evaluating the expression of RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer therapeutics. Our review focuses mainly on the current clinical research regarding ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.

Keywords: EGFR; HER2; HER3; ImmunoPET; PET/CT; RTK; VEGF; receptor tyrosine kinases.

Publication types

  • Review

Grants and funding

This research received no external funding.